订阅小程序
旧版功能

Prospective Monitoring of Immune Signatures in Newly Diagnosed High Risk Multiple Myeloma Patients under Treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-Krd): First Results of the GMMG-CONCEPT Trial

A. M. Asemissen,S. E. Autenrieth,K. Bieber,C. Gouttefangeas,H. -G. Rammensee,B. Besemer,C. Mann,I. -W. Blau,A. Schieferdecker,C. Bokemeyer,H. Goldschmidt,K. Weisel

Clinical Lymphoma Myeloma & Leukemia（2019）

引用 4|浏览41
关键词
High risk,immunophenotype,isatuximab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要